A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates (2020)

Stone, V. M., Hankaniemi, M.M., Laitinen, O. H., Sioofy-Khojine, A. B., Lin, A., Diaz Lozano, I. M., Mazur, M. A., Marjomäki, V., Loré, K., Hyöty, H., Hytönen, V. P., & Flodström-Tullberg, M. (2020). A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Science Advances, 6(19), Article eaaz2433. https://doi.org/10.1126/sciadv.aaz2433

JYU-tekijät tai -toimittajat

Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Stone, V. M.; Hankaniemi, M. M.; Laitinen, O. H.; Sioofy-Khojine, A. B.; Lin, A.; Diaz Lozano, I. M.; Mazur, M. A.; Marjomäki, V.; Loré, K.; Hyöty, H.; et al.

Lehti tai sarja: Science Advances

eISSN: 2375-2548

Julkaisuvuosi: 2020

Volyymi: 6

Lehden numero: 19

Artikkelinumero: eaaz2433

Kustantaja: American Association for the Advancement of Science

Julkaisumaa: Yhdysvallat (USA)

Julkaisun kieli: englanti

DOI: https://doi.org/10.1126/sciadv.aaz2433

Julkaisun avoin saatavuus: Avoimesti saatavilla

Julkaisukanavan avoin saatavuus: Kokonaan avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/69009

Tiivistelmä

Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.

YSO-asiasanat: enterovirukset; rokotteet; vasta-aineet; immuniteetti; nuoruustyypin diabetes; koe-eläinmallit

Liittyvät organisaatiot

OKM-raportointi: Kyllä

Raportointivuosi: 2020

JUFO-taso: 3